Please ensure Javascript is enabled for purposes of website accessibility

Why Aldeyra Therapeutics Stock Is Soaring Today

By Keith Speights - Updated Apr 27, 2021 at 11:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported great clinical results for its lead pipeline candidate.

What happened

Shares of Aldeyra Therapeutics (ALDX -4.76%) were soaring 26.6% higher as of 10:54 a.m. EDT on Tuesday. The big jump came after the company announced positive top-line results from a late-stage study evaluating reproxalap in treating allergic conjunctivitis, inflammation of the eyes caused by allergies.

So what

Biotech stocks usually rise on positive clinical results. But the really big gains come when the results are especially good. That's the case for Aldeyra.

Woman applying eye drops

Image source: Getty Images.

Reproxalap easily achieved the primary endpoint of the study (reduction in eye itching) with a high level of statistical significance. It also achieved all of the secondary endpoints of the study with high levels of statistical significance.

The results were exactly what investors were hoping for. They weren't really surprising, though. Aldeyra previously reported positive results from another late-stage study of reproxalap in treating allergic conjunctivitis.

More than 66 million people in the U.S. are affected by allergic conjunctivitis. While some treatments are available, there hasn't been a new therapeutic mechanism in decades. 

Now what

Aldeyra's next step is to meet with the U.S. Food and Drug Administration (FDA) about a path to approval for reproxalap. This meeting is expected to take place in the second half of this year, with a potential regulatory filing for approval on the way afterward.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aldeyra Therapeutics, Inc. Stock Quote
Aldeyra Therapeutics, Inc.
$3.80 (-4.76%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.